Atrial natriuretic factor (ANF) is a peptide hormone of cardiac origin elevated in acute congestive heart failure (CHF), which is degraded by the enzyme neutral endopeptidase 24.11 (NEP). This study was designed to investigate the pulmonary and urinary clearance of ANF before and after the initiation of acute experimental CHF in dogs, and to assess the contribution of enzymatic degradation to these clearances in CHF. This study demonstrated a significant clearance of plasma ANF across the pulmonary circulation at baseline, and a tendency for pulmonary clearance to decrease in CHF (1115±268 to 498±173 ml/ min, NS). The pulmonary extraction of ANF present at baseline was not altered with acute CHF (36.0±7.8 to 34.9±12.1%, NS). NEP inhibition (NEPI) abolished both the clearance and extraction of plasma ANF across the lung in CHF. Similarly, a significant urinary clearance of ANF was present at baseline, and in acute CHF the urinary clearance of ANF decreased (0.14±0.02 to 0.02±0.01 ml/min, P < 0.05). NEPI prevented the decrease in the urinary clearance of ANF, and enhanced the renal response to endogenous ANF, independent of further increases in plasma ANF during CHF. This study supports an important role for NEP in the pulmonary and urinary metabolism of endogenous ANF during acute CHF. (J. Clin. Invest.
Introduction
Atrial natriuretic factor (ANF)' is a peptide hormone of cardiac origin, which circulates as a 28-amino acid peptide and contains a 17-member ring formed by a cysteine-cysteine disulfide bond. ANF is released in response to atrial stretch and participates in the physiologic regulation of sodium excretion, venous return, and the renin-angiotensin system (1-7). Al-though congestive heart failure (CHF) is known to be associated with increases in circulating ANF (5) , an understanding ofANF degradation in CHF is less clear. Binding ofthe peptide to biologically inactive clearance receptors (8) , and degradation of the peptide via the enzyme system neutral endopeptidase 24.11 (NEP) (9) (10) (11) (12) , are two clearance mechanisms for ANF.
Berg and colleagues have reported that ANF is rapidly degraded by the kidney, in part via a nonsaturable NEP localized to the luminal membrane of the proximal tubule (9) Berg et al. Although the kidney has been accepted as a major site of ANF clearance (9, 10, 11, 13, 14, 15) , studies conflict with regard to the existence of pulmonary clearance of ANF (16) (17) (18) (19) . Hollister and colleagues have proposed a significant contribution of the lung to ANF clearance (20) , which is relevant to recent studies which have demonstrated significant NEP activity in the lung (21) . While these studies support a role for the lung and kidney in the clearance of ANF via NEP, the pulmonary and urinary clearance of ANF in vivo remains unclear. Moreover, the pulmonary and urinary ANF clearance in CHF, a state characterized by marked increases in circulating ANF, also has not been investigated.
Therefore, the objective of this study was to determine the pulmonary and urinary clearance of ANF before and after the initiation of acute experimental CHF. A second objective of the study was to assess the contribution of enzymatic degradation of the atrial peptide to the urinary and pulmonary clearance of ANF in CHF by using a specific inhibitor of neutral endopeptidase 24.1 1 (NEPI) (22, 23) . A third objective ofthese investigations was to define the cardiovascular and renal effects of NEPI in the presence of acute CHF.
Methods
Surgical preparation. Experiments were conducted in two groups of anesthetized dogs (n = 6 pergroup) weighing 19 -24 kg, with experimental acute CHF induced by rapid right ventricular pacing. This model is characterized by alterations in cardiorenal function and circulating hormones as observed in humans with acute biventricular heart failure (4, 23, 24) .
The dogs were fasted overnight 16 h before the acute experiment and allowed to drink water ad libitum until the time ofthe experiment. Dogs were anesthetized with sodium pentobarbital (30 mg/kg i.v.), and supplemental doses were given as necessary to maintain anesthesia. The dogs were then intubated and artificially ventilated (Harvard respirator; Harvard apparatus, Millis, MA) with supplemental oxygen at 4 liters per minute.
Surgical preparation in the acute experiment was as follows: the right external jugular vein was cannulated with a flow-directed, balloon-tipped, thermodilution catheter (model 93A-3 31-7F; American Edwards Laboratory, Anasco, Puerto Rico) and advanced into the pulmonary artery for measurement ofcardiac filling pressures, determination of cardiac output, and pulmonary artery sampling. The heart was exposed via a left thoracotomy incision at the fourth intercostal space, the pericardium was opened, and an epicardial pacemaker lead was placed on the right ventricle to induce CHF. The left lung was retracted and a minor pulmonary vein cannulated for indirect monitoring ofleft atrial pressure and pulmonary vein sampling. The right femoral artery was cannulated for measurement of arterial pressure and sampling of arterial blood, and femoral veins were cannulated for infusion of inulin, NEPI, or supplemental anesthesia. The left kidney was exposed via a flank incision and the ureter cannulated for timed urine collections. An electromagnetic flow probe (Carolina Medical Electronics, King, NC) was placed on the left renal artery for on-line monitoring of renal blood flow.
Experimental protocol. Upon completion of the surgical preparation, an inulin and saline solution was infused via a femoral vein catheter at I ml/min to achieve a plasma concentration of -50 mg/dl. The dogs were then allowed to stabilize for 60 min without intervention. At the end ofthe equilibration period, one 30-min baseline clearance was obtained. Each clearance period consisted ofa 30-min urine collection, measurement of hemodynamic parameters (midpoint of each clearance period), and withdrawal of 25 cc of arterial blood for hormone analysis and electrolyte determination.
After the surgical preparation, equilibrium period, and a baseline 30-min clearance, rapid right ventricular pacing was initiated for 3 h to induce acute CHF (the pacing rate was adjusted to induce a 15% drop in mean arterial pressure). This model has previously been used in our laboratory (24, 25) . After the first 30 min of pacing to allow for adjustments in pacing rate according to the hemodynamic parameters, the vehicle or NEPI was initiated in the groups. The remainder of the protocol differed among the two experimental groups. Group I: intravenous bolus infusion of a vehicle (0.84% bicarbonate solution) given over 5 min, followed by clearances every 30 min throughout the 3 h of acute pacing to serve as a control group. Group II: intravenous bolus infusion ofthe neutral endopeptidase inhibitor (SQ 28,603), 60 mg/kg, dissolved in the above vehicle, and given over 5 min, followed by clearances every 30 min throughout the 3 h of acute pacing. SQ 28, 603 (N-[24mercaptomethyl)--oxo-3-phenylpropyl]-fl-alanine) isacompetitive inhibitor of neutral endopeptidase 24.1 1, selective in action with only weak activity against other renal brush border peptidases, such as angiotensin converting enzyme and aminopeptidase M (Delaney, N. G., unpublished data). Additional blood samples were obtained simultaneously from the pulmonary artery and pulmonary vein catheters at baseline and 60 min after NEPI or vehicle infusion for determination of the pulmonary extraction and clearance of ANF.
Analyses. Blood for plasma sodium and inulin measurement was placed in heparinized tubes on ice, centrifuged at 2,500 rpm and 3°C, and refrigerated pending analysis. Plasma and urinary sodium concentrations were measured using ion-selective electrodes (Beckman Instruments, Brea, LA). Plasma and urinary inulin concentrations were determined by the anthrone method (25) . Blood for hormone assay was placed in EDTA tubes and immediately placed on ice, after centrifugation at 2,500 rpm and 3°C, the plasma was decanted and stored at -20°C until analysis. Urine was collected on ice and stored at -20°C until analysis. The urine undergoing analysis for cGMP was heated to > 90°C before storage. Plasma and urinary ANF and cyclic guanosine monophosphate (cGMP) were measured by a specific RIA, as previously described (5, 26, 27) . The RIA technique used in this study was tested and revealed no interference with the urinary immunoassay for ANF in dogs receiving NEPI. The urine was also analyzed with a gel filtration P-6 column to assess the molecular form ofANF in the urine. Concentrations ofimmunoreactive ANF-separated fractions were then determined by RIA to a-ANF (28) . Glomerular filtration rate (GFR) was determined by inulin clearance. Hemodynamic data included mean arterial pressure (MAP), right atrial pressure (RAP), pulmonary vein pressure to assess left atrial pressure (LAP), renal blood flow (RBF), and cardiac output (CO). CO was measured by thermodilution technique and determined via the average of four measurements. Cal- Statistics. For each experimental group, data from all clearance periods was measured and expressed as mean±SEM. All data was assessed by Student's paired t tests for comparisons of absolute changes within each group. One sample hypothesis testing was used to determine the existence of the pulmonary and urinary clearance of ANF at baseline. Statistical significance was accepted for P < 0.05.
Results
The cardiovascular, renal, and endocrine data for the two experimental groups are summarized in Tables I, II , and III. At baseline, in the presence of physiologic concentrations of plasma ANF, there was significant pulmonary extraction (PExANF) and clearance (PCLANF) of ANF in both groups (P < 0.05). Urinary clearance of ANF (UcLANF) was also present in both groups (P < 0.05) at baseline. Vehicle group. In the vehicle group (group 1), the initiation ofCHF was associated with significant systemic hemodynamic changes including decreases in MAP and CO, and increases in atrial pressures and systemic vascular resistance (SVR). As expected, marked increases in plasma ANF were observed in acute CHF (Fig. 1 ) and were associated with significant increases in plasma cGMP concentrations. As plasma ANF increased in acute CHF, UCLANF tended to decrease. Although these changes did not achieve statistical significance initially, as CHF continued, UCLANF remained significantly decreased below baseline levels (Fig. 3) . Associated with the decrease in UCLANF, there was no change in GFR, urine flow, or urinary sodium excretion. PEXANF did not change with the onset of CHF in the vehicle group (Fig. 2 a) . The PCLANF tended to decrease in this group in association with decreases in cardiac output, however this PcLANF decrease did not reach statistical significance (Fig. 2 b) .
NEPI group. In group 2, in the presence of NEPI and acute CHF, no decrease in UcLANF was observed, and UCLANF actually tended to increase (Fig. 3) . The absolute changes in plasma and urine ANF concentrations are compared between the two groups in Fig. 4 . Fractional excretion of ANF (FE ANF), a marker of renal tubular handling offiltered peptide, followed a similar pattern suggesting decreased tubular degradation of ANF in the presence of NEPI. Analysis of the urine with gel filtration chromatography (28) reveals the major molecular form of ANF in the urine after NEPI to be a-ANF (Fig. 5) .
Regarding the pulmonary handling of ANF, PEXANF and PcLANF were abolished in the presence of NEPI (Fig. 2, a and  b) . In acute CHF, after NEPI administration, circulating plasma ANF levels did not increase further (Fig. 1) , although plasma cGMP did continue to increase. tissue uptake, and protease degradation. NEP In previous studies, the renal response to NEPI, in dogs ently been shown to be present within the lung with and without chronic CHF, was characterized by a signifingly, pathophysiologic conditions that cause elecant diuresis and natriuresis without increases in GFR or RBF sma ANF also produce elevated levels of NEP (22, 23 (46) . One must however be cautious in interpreting this increase in urinary ANF despite the increases in both urinary cGMP and sodium, as this assay technique may detect open-ringed peptide. Other mechanisms such as increased GFR after NEPI, may also be considered as contributing to the renal response. While the urinary excretion of ANF and cGMP remained elevated during the recovery period, urinary excretion of sodium declined. This phenomena may best be explained by the decrease in MAP and renal perfusion pressure during the recovery period (47) .
The NEPI employed in this experiment, SQ 28,603, has minimal activity against other brush border enzymes, such as angiotensin converting enzyme and aminopeptidase M. However, the activity of SQ 28,603 upon peptidases outside the brush border of the nephron is not known. NEP has been shown, via in vitro analysis, to hydrolyze other factors such as kinins (48, 49) . Because the influence of NEPI on these other factors was not assessed in this study, we can not exclude their contribution to the observed hemodynamic and renal responses, although studies using a monoclonal antibody to ANF in rats with CHF (50) have suggested that potentiation of ANF activity is a major contributor to the observed renal responses of NEPI.
In summary, these studies demonstrate a significant clearance of plasma ANF across the pulmonary circulation under normal physiologic conditions. Although the PcLANF tended to decrease during acute CHF, the PExANF was not altered. The administration of NEPI during acute CHF abolished both the clearance and the extraction of plasma ANF across the lung, supporting a significant role for NEP in the pulmonary degradation of ANF. Analogously, we observed a significant UCLANF under normal physiologic conditions. In CHF, marked decreases in UCLANF and FE ANF were observed, consistent with enhanced urinary degradation of the peptide.
These decreases in UCLANF and FE ANF, despite the marked increases ofplasma ANF during acute CHF, suggest the nonsaturability of NEP within the kidney in vivo. NEPI prevented the decreases in UCLANF and FE ANF, and enhanced the renal response to endogenous ANF, independent offurther increases in circulating plasma ANF concentrations during acute CHF. These enhanced renal responses and observed effects upon cardiac hemodynamics may be mediated by the potentiation of endogenous ANF as manifested by increases in urinary and plasma cGMP. These studies importantly support a role for NEP in the in vivo metabolism of endogenous ANF during CHF. These studies also support a role for NEPI in potentiating the actions of endogenous ANF in acute CHF.
